Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraurethral and topical agents.

R W Lewis1

  • 1Medical College of Georgia, Section of Urology, Augusta, Georgia 30913-4050, USA.

Drugs of Today (Barcelona, Spain : 1998)
|July 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Considerations for the development of guidance on dose level selection for developmental and reproductive toxicity studies.

Regulatory toxicology and pharmacology : RTP·2024
Same author

'Concord' grapevine nutritional status and chlorosis rank associated with fungal and bacterial root zone microbiomes.

Plant physiology and biochemistry : PPB·2018
Same author

The rate of torque development: a unique, non-invasive indicator of eccentric-induced muscle damage?

International journal of sports medicine·2014
Same author

"Touched pitch and been shockingly defiled": football, class, social Darwinism and decadence in England, 1880-1914.

The European sports history review·2011
Same author

Eye irritation: Reference chemicals data bank.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

An interlaboratory assessment of the Eytex system.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

The MUSE system, a urethral suppository with alprostadil, effectively treats impotence, with 64.9% of users achieving intercourse. This treatment shows consistent results and is suitable for various impotence categories.

Area of Science:

  • Urology
  • Pharmacology
  • Andrology

Background:

  • Erectile dysfunction (ED) affects a significant patient population.
  • Transurethral drug delivery systems offer an alternative to other ED treatment modalities.
  • Alprostadil (prostaglandin E1) is a vasodilator with potential for ED treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of the MUSE (Medicated Urethral System for Erection) system for treating erectile dysfunction.
  • To assess patient-reported outcomes and satisfaction with home use of alprostadil urethral suppositories.
  • To compare the effectiveness of MUSE with placebo in a patient population with erectile dysfunction.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 873 patients with erectile dysfunction.

Related Experiment Videos

  • Patients self-administered alprostadil or placebo urethral suppositories at home.
  • Efficacy was assessed by patient-reported success rates for intercourse and consistency of response over time.

    • Main Results:

    • 64.9% of patients using alprostadil reported successful intercourse compared to 18.6% in the placebo group.
    • The MUSE system demonstrated efficacy across all categories of impotence.
    • Adverse events included penile pain (32.1%) and minor urethral trauma (5.1%).
    • Patients for whom intracavernosal injections were ineffective showed a 58% success rate with MUSE.

    Conclusions:

    • The MUSE system provides an effective and well-tolerated treatment option for erectile dysfunction.
    • Home use of alprostadil urethral suppositories offers a viable alternative for managing ED.
    • Further studies explored combination therapy with the MUSE system and veno-occlusive bands.